Administering rituximab repeatedly may improve the response of patients with ANCA-associated vasculitis (AAV) to the medication, a study…
Articles by Joana Carvalho, PhD
Intravenous immunoglobulin (IVIG) therapy leads to a fast and significant reduction in disease activity, as well as in the…
Dividing people with active ANCA-associated vasculitis (AAV) into different subgroups may be useful for determining prognosis and selecting…
The formation, composition, and structure of antimicrobial traps in ANCA-associated vasculitis (AAV) patients are markedly different from those with…
People with ANCA-associated vasculitis with high levels of myeloperoxidase (MPO) antibodies at diagnosis are more likely to have poor…
The Birmingham Vasculitis Activity Score (BVAS) and the Five Factors Score (FFS) are both useful tools for predicting…
A combination of Rituxan (rituximab) and Soliris (eculizumab) may be used to replace glucocorticoids for the…
The first patient has been dosed in InflaRx‘s ongoing European Phase 2 clinical trial testing the safety and…
ChemoCentryx remains on track to report topline results later this year from its ongoing Phase 3 clinical trial assessing…
Some patients with microscopic polyangiitis (MPA) produce antibodies against antimicrobial traps that may partly explain why these traps are capable…